CMA
JAZZ icon

Cedar Mountain Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Cedar Mountain Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.7K Hold
115
– – ﹤0.01% 268
2026
Q1 		$21.7K Buy
+115
New +$20.1K ﹤0.01% 279

Other funds holding JAZZ

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.17B AUM 36.16% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
PL
Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
BCM
BTC Capital Management Des Moines, Iowa $1.65B AUM 27.85% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BC
Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

Cedar Mountain Advisors's JAZZ Position: Q2 2026 in Review

Cedar Mountain Advisors held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 115 shares worth $27.7K. The position accounts for ﹤0.01% of the portfolio, ranked #268.

Cedar Mountain Advisors first reported a position in JAZZ in Q1 2026 and has held it in 2 quarters since. 69 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Cedar Mountain Advisors held 115 shares of Jazz Pharmaceuticals worth $27.7K as of Q2 2026.
  • Cedar Mountain Advisors left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #268 holding.
  • Cedar Mountain Advisors first reported a position in Jazz Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 69 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.